Dyne Therapeutics (NASDAQ:DYN) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Dyne Therapeutics (NASDAQ:DYN) issued its quarterly earnings data on Monday. The company reported ($0.70) EPS for the quarter, beating the consensus estimate of ($0.72) by $0.02, Zacks reports.

Dyne Therapeutics Stock Up 1.3 %

DYN traded up $0.57 during trading on Tuesday, hitting $43.64. The company’s stock had a trading volume of 962,248 shares, compared to its average volume of 1,591,091. Dyne Therapeutics has a one year low of $6.40 and a one year high of $45.46. The firm has a market cap of $3.81 billion, a PE ratio of -10.77 and a beta of 1.07. The business’s 50 day simple moving average is $37.89 and its 200-day simple moving average is $30.32.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on DYN. Oppenheimer restated an “outperform” rating and issued a $47.00 price objective on shares of Dyne Therapeutics in a report on Monday, May 6th. HC Wainwright upped their price objective on shares of Dyne Therapeutics from $48.00 to $55.00 and gave the stock a “buy” rating in a report on Tuesday. JPMorgan Chase & Co. upped their price objective on shares of Dyne Therapeutics from $39.00 to $43.00 and gave the stock an “overweight” rating in a report on Tuesday, July 9th. Chardan Capital upped their price objective on shares of Dyne Therapeutics from $31.00 to $42.00 and gave the stock a “buy” rating in a report on Tuesday, May 21st. Finally, Piper Sandler increased their price target on shares of Dyne Therapeutics from $43.00 to $53.00 and gave the company an “overweight” rating in a report on Tuesday. One research analyst has rated the stock with a sell rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $46.56.

Insiders Place Their Bets

In other news, COO Susanna Gatti High sold 10,163 shares of the firm’s stock in a transaction on Monday, June 24th. The shares were sold at an average price of $35.33, for a total transaction of $359,058.79. Following the sale, the chief operating officer now directly owns 148,792 shares in the company, valued at approximately $5,256,821.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, insider Oxana Beskrovnaya sold 2,705 shares of the firm’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $28.27, for a total transaction of $76,470.35. Following the sale, the insider now directly owns 149,647 shares in the company, valued at approximately $4,230,520.69. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Susanna Gatti High sold 10,163 shares of the firm’s stock in a transaction on Monday, June 24th. The shares were sold at an average price of $35.33, for a total transaction of $359,058.79. Following the sale, the chief operating officer now owns 148,792 shares in the company, valued at $5,256,821.36. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 202,133 shares of company stock worth $6,500,387. Company insiders own 20.77% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.